Journal of the Formosan Medical Association最新文献

Viral associations with hematologic cancers. 病毒与血液学癌症的关系

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-07-02 DOI: 10.1016/j.jfma.2025.07.001

Mark Stasiewicz, Tomasz M Karpiński

{"title":"Viral associations with hematologic cancers.","authors":"Mark Stasiewicz, Tomasz M Karpiński","doi":"10.1016/j.jfma.2025.07.001","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.07.001","url":null,"abstract":"Hematologic malignancies (HMs) continue to present a burden upon healthcare systems worldwide, with over one million incident cases reported in 2020 alone. It has been known for decades that infectious agents serve as the etiologic agents for a number of neoplastic disorders and outright cancers. Viruses are the predominant infectious contributor to oncogenesis among HMs. The PubMed database was utilized to outline the present state of understanding as it relates to viral associations with HMs. Viruses with the most evidence supporting their association with the development of HMs include Epstein-Barr virus, human immunodeficiency virus, human T-lymphotropic virus, hepatitis C virus and Kaposi sarcoma herpesvirus. Reactivation of latent hepatitis B virus is associated with treatment regimens commonly used in the management of HMs. Furthermore, brief summaries of the oncogenic mechanisms underlying the aforementioned associations and an overview of current management principles are presented. Such information may serve to guide clinicians in establishing the etiology of their patients' malignancy and help establish best practices to prevent the spread and reactivation of viruses associated with the development and treatment of HMs.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between anticholinergic drug use and hepatic encephalopathy risk among patients with cirrhosis. 肝硬化患者抗胆碱能药物使用与肝性脑病风险的关系

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-30 DOI: 10.1016/j.jfma.2025.06.038

Hsin-Ni Shih, Chung-Hsuen Wu, Yuan-Wen Lee, Chun-Chao Chang

{"title":"Association between anticholinergic drug use and hepatic encephalopathy risk among patients with cirrhosis.","authors":"Hsin-Ni Shih, Chung-Hsuen Wu, Yuan-Wen Lee, Chun-Chao Chang","doi":"10.1016/j.jfma.2025.06.038","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.06.038","url":null,"abstract":"Background: Anticholinergic drugs reduce gastric acid production and induce constipation, both of which are associated with gut dysbiosis. Medication-induced changes in gut flora may lead to hepatic encephalopathy in patients with cirrhosis. This study aimed to evaluate the association between anticholinergic drug use and the risk of hepatic encephalopathy among patients with cirrhosis.Methods: This retrospective cohort study included patients with cirrhosis (age ≥20 years), identified from the Health and Welfare Database in Taiwan with the study period from 2007 to 2018. The included patients were categorized into two groups: anticholinergic drug users-those who received oral anticholinergic drugs with continuous refills without a gap of 28 days over a 180-day exposure period-and nonusers. The outcome was the incidence of hepatic encephalopathy. To address confounding effects, we performed propensity score matching and inverse probability of treatment weighting. Using Cox proportional-hazard regression models, we investigated the association between anticholinergic drug use and hepatic encephalopathy risk among patients with cirrhosis.Results: The study cohort included 10,607 cirrhotic patients; of them, 33.8 % were anticholinergic drug users. Among these patients, anticholinergic drug users were found to be associated with a significantly increased risk of hepatic encephalopathy (adjusted hazard ratio: 2.59: 95 % confidence interval: 1.77-3.80).Conclusion: Anticholinergic drug users were at a significantly higher risk of hepatic encephalopathy among patients with cirrhosis in Taiwan. Thus, anticholinergic drugs should be prescribed cautiously, and the cognitive performance of patients with cirrhosis who use these drugs should be monitored regularly.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence. 蛋白亚基SARS-CoV-2疫苗MVC-CoV1901和NVX-CoV2373对利妥昔单抗治疗的免疫介导炎症性疾病患者的潜在保护优势：真实世界证据

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-26 DOI: 10.1016/j.jfma.2025.06.029

Pei-Hsinq Lai, Ting-Yuan Lan, Cheng-Hsun Lu, Song-Chou Hsieh

{"title":"Potential protective advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373, in patients with rituximab-treated immune-mediated inflammatory diseases: Real-world evidence.","authors":"Pei-Hsinq Lai, Ting-Yuan Lan, Cheng-Hsun Lu, Song-Chou Hsieh","doi":"10.1016/j.jfma.2025.06.029","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.06.029","url":null,"abstract":"Since the COVID-19 pandemic, patients with immune-mediated inflammatory diseases (IMID) are recommended to receive SARS-CoV-2 vaccinations to reduce complications following COVID-19 infection. We conducted a case-control study and case analysis to investigate how SARS-CoV-2 vaccine platforms impact COVID-19 outcomes in patients with IMID on chronic rituximab therapies. Our findings suggest that exposure to protein-subunit vaccines were associated with the lowest mortality rates. Specifically, in the multivariate analysis of patients hospitalized for COVID-19, protein-subunit vaccines provided protection against all-cause mortality, particularly in those with lower pre-COVID-19 albumin levels, a surrogate for higher pre-COVID-19 inflammation. These results highlight the potential protective advantages of the protein-subunit vaccines, MVC-CoV1901 and NVX-CoV2373 vaccine, in patients with IMID. Moreover, our data supports heterologous vaccine regimens incorporating protein-subunit vaccines as a viable strategy for patients with IMID. Given the small sample size, further studies are needed to validate the clinical implications of this study.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospective longitudinal study of patient-reported dysphagia in nasopharyngeal carcinoma treated with intensity-modulated proton therapy. 调强质子治疗鼻咽癌患者报告的吞咽困难的前瞻性纵向研究。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-26 DOI: 10.1016/j.jfma.2025.06.035

Yu-Jie Huang, Shang-Yu Chou, Ming-Hsien Tsai, Hui-Ching Chuang, Chih-Yen Chien, Wen-Ling Tsai, Fu-Min Fang, Yan-Ye Su

{"title":"Prospective longitudinal study of patient-reported dysphagia in nasopharyngeal carcinoma treated with intensity-modulated proton therapy.","authors":"Yu-Jie Huang, Shang-Yu Chou, Ming-Hsien Tsai, Hui-Ching Chuang, Chih-Yen Chien, Wen-Ling Tsai, Fu-Min Fang, Yan-Ye Su","doi":"10.1016/j.jfma.2025.06.035","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.06.035","url":null,"abstract":"Purpose: To evaluate longitudinal changes in patient-reported dysphagia and identify its predictors in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated proton therapy (IMPT).Methods: Newly diagnosed, non-metastatic NPC patients were prospectively enrolled. The MD Anderson Dysphagia Inventory (MDADI) was administered at seven time points from baseline to 12 months post-IMPT. Primary endpoints included: (1) clinically significant decline (CSD), defined as a ≥10-point decrease in MDADI composite score from baseline to end of IMPT, and (2) no recovery to baseline (NRB) at 12 months. Clinical, sociodemographic, and dosimetric variables were analyzed.Results: Of 58 patients, 49 completed MDADI assessments at all time-points. CSD occurred in 69 %, and NRB in 34 %. Patients with CSD had significantly higher mean doses to the oral cavity and superior pharyngeal constrictor muscle (S-PCM) (p < 0.05), while those with NRB had higher doses to the oral cavity, S-PCM, and middle PCM (M-PCM) (p < 0.01). After adjustment clinical and sociodemographic variables, independent predictors of CSD were mean dose to oral cavity (OR = 1.210) and S-PCM (OR = 1.249). Predictors of NRB included mean dose to oral cavity (OR = 1.268), S-PCM (OR = 1.211), and M-PCM (OR = 1.166). Limiting mean doses below 12.2Gy[RBE] (oral cavity) and 55.4Gy[RBE] (S-PCM) reduced CSD risk to <0.6 and NRB risk to <0.2, respectively; a dose below 36.1 Gy[RBE] (M-PCM) reduced NRB risk to <0.2.Conclusion: Minimizing mean doses to the oral cavity, S-PCM, and M-PCM is crucial for reducing patient-reported dysphagia following IMPT in NPC patients.","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on "serum neutrophil gelatinase-associated lipocalin as a potential biomarker of diabetic kidney disease in patients with childhood-onset type 1 diabetes". 关于“血清中性粒细胞明胶酶相关脂钙蛋白作为儿童发病1型糖尿病患者糖尿病肾病的潜在生物标志物”的评论。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-24 DOI: 10.1016/j.jfma.2025.06.032

Qiang Zhang, Jiaojiao Yue, Yang He, Na Zhang

引用次数: 0

Comment on: Fewer good-quality cleavage embryos in dydrogesterone-primed ovarian stimulation compared to GnRH antagonist protocol in POSEIDON group 4 patients. 点评：在POSEIDON第4组患者中，与GnRH拮抗剂方案相比，地孕酮诱导卵巢刺激的优质卵裂胚胎较少。

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-24 DOI: 10.1016/j.jfma.2025.06.037

引用次数: 0

Authorship statement 作者声明

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-23 DOI: 10.1016/S0929-6646(25)00316-X

引用次数: 0

Checklist 检查表

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-23 DOI: 10.1016/S0929-6646(25)00315-8

引用次数: 0

Guide for Authors 作者指南

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-23 DOI: 10.1016/S0929-6646(25)00314-6

引用次数: 0

Copyright transfer statement 版权转让声明

IF 2.6 3区医学

Journal of the Formosan Medical Association Pub Date : 2025-06-23 DOI: 10.1016/S0929-6646(25)00317-1

引用次数: 0